Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7758685 | 0.92 | PDE4A (0.33) | HPRT1 | |
| SCHEMBL8343189 | 0.83 | PDE4A (0.35) | HPRT1 | |
| SCHEMBL5048171 | 0.81 | PNP (0.39) | — | |
| SCHEMBL8343186 | 0.80 | HPRT1 (0.31) | HPRT1 | |
| SCHEMBL7758704 | 0.76 | PDE4A (0.39) | — | |
| SCHEMBL6265333 | 0.75 | PDE4A (0.46) | — | |
| SCHEMBL5091257 | 0.75 | CYP2C19 (0.30) | — | |
| SCHEMBL6265529 | 0.74 | PDE4A (0.34) | — | |
| SCHEMBL6267419 | 0.73 | PNP (0.40) | — | |
| SCHEMBL6268075 | 0.72 | ADORA2A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189941-B1 | NEUROMEDIN B AND SOMATOSTATIN RECEPTOR AGONISTS | IPSEN PHARMA (FR) | 2013-01-09 | — | — | EP | disclosed |
| US-20080132453-A1 | Neuromedin B and somatostatin receptor agonists | IPSEN PHARMA S.A.S. (FR) | 2008-06-05 | — | — | US | disclosed |
| US-6903074-B1 | Neuromedin b and somatostatin receptor agonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2005-06-07 | — | — | US | disclosed |
| EP-1189941-A1 | NEUROMEDIN B AND SOMATOSTATIN RECEPTOR AGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000075186-A1 | NEUROMEDIN B AND SOMATOSTATIN RECEPTOR AGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES SAS (FR) | 2000-12-14 | — | — | WO | disclosed |
| US-5977296-A | MONOMERS WITH ALIPHATIC CYCLIC STRUCTURE IN THE BACKBONE; FOR INCREASED CONFORMATION RESTRICTION LEADING TO INCREASED BINDING AFFINITY AND SPECIFICITY; FOR DETECTING POINT MUTATIONS, FOR SUPPRESSING WILD TYPE GENES IN AMPLIFICATION | NIELSEN, PETER E. (DK) | 1999-11-02 | — | — | US | disclosed |
| WO-1996020212-A2 | PEPTIDE NUCLEIC ACID INCORPORATING A CHIRAL BACKBONE | BUCHARDT, DORTE (DK) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132453-A1 | Neuromedin B and somatostatin receptor agonists | NMBR, NMUR1, NMUR2 | HPRT1 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.